Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT05956041Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, mogamulizumab in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), Sézary syndrome (SS), sponsored by University of Michigan Rogel Cancer Center. Started Dec 2023; status: recruiting.
02
Drugs
pembrolizumabmogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT05956041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956041.